During the COVID-19 pandemic, much focus has been placed on the
importance of non-disruption to the EU medicines supply chain for
humans, and the development of new medicines for the fight against
COVID-19.
Steps have, however, also been taken in respect of veterinary
medicines, which face the same concerns regarding supply chain
disruption as their human counterparts. In this vein, the European
Commission, European Medicines Agency
("EMA"), the Coordination Group for
Mutual Recognition and Decentralised Procedure - Veterinary and the
Heads of Medicines Agencies network has published a guidance note on regulatory flexibility for
veterinary medicines during the COVID-19 pandemic. The guidance
note details an adapted regulatory framework applicable to
companies that develop, manufacture and distribute veterinary
medicines. It is aimed at addressing some of the supply chain
obstacles that have been caused by the pandemic.
